Clinical Trial: Metabiomics Colon Cancer Clinical Research Study

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Observational

Official Title: Metabiomics Colon Cancer Clinical Research Study

Brief Summary: The specific aim of the study is to determine the false negative rate of the Metabiomics Colon Polyp and Colorectal Cancer Assay for Cancer.

Detailed Summary: The purpose of this study is to conduct clinical research to investigate the association of the gut microbiome with colonic neoplasia. In this case several types of gut microbiome samples will be collected from patients undergoing colectomy for colonic adenocarcinoma; those samples will be tested by Metabiomics Colon Polyp and Colorectal Cancer Assay and the percentage of false negative (test returns a negative for cancer) results determined.
Sponsor: Metabiomics Corp

Current Primary Outcome: False negative rate of test for colon cancer [ Time Frame: immediately post surgery ]

The False Negative Rate is calculated as (100*False Negative) /(True Positive + False Negative).


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Metabiomics Corp

Dates:
Date Received: May 27, 2014
Date Started: August 2016
Date Completion: December 2018
Last Updated: March 29, 2016
Last Verified: March 2016